Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Free Radical Biology

Background:

• Myocardial infarction (MI) involves significant tissue damage.
• Iron overload can exacerbate oxidative stress and infarct size.
• Iron chelators are potential therapeutic agents for MI.

Purpose of the Study:

• To evaluate the efficacy of desferrioxamine, an iron chelator, in reducing infarct size in a rat model of myocardial infarction.
• To investigate the mechanism underlying desferrioxamine's potential cardioprotective effects.

Main Methods:

• Myocardial infarction was induced in rats via coronary artery ligation (CAL).
• Desferrioxamine was administered intravenously at 10 mg/kg and 20 mg/kg doses post-CAL.
• Infarct size was quantified using 2,3,5-triphenyltetrazolium chloride (TTC) staining.
• Systolic blood pressure and electrocardiography (ECG) were monitored.
• Inhibition of polymorphonuclear neutrophil (PMN)-evoked chemiluminescence was assessed in vitro and in vivo.

Main Results:

• Desferrioxamine administration significantly reduced myocardial infarct size in a dose-dependent manner.
• No significant alterations in systolic blood pressure were observed following desferrioxamine treatment.
• Desferrioxamine inhibited both in vitro and in vivo rat PMN-evoked chemiluminescence.
• The drug demonstrated a capacity to impair oxygen free radical generation or act as a free radical scavenger.

Conclusions:

• Desferrioxamine exhibits significant cardioprotective effects against myocardial infarction in rats.
• The mechanism of action likely involves the modulation of oxidative stress through iron chelation and/or free radical scavenging.
• Desferrioxamine represents a promising therapeutic strategy for mitigating infarct size in myocardial infarction.